Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the cost of each quality-adjusted life year added to 5 to 11 year old children as a result of offering that cohort a covid-19 vaccination.
Answered by Maggie Throup
On 22 December 2021, the Government accepted the advice of the Joint Committee on Vaccination and Immunisation (JCVI) to offer COVID-19 vaccinations to children aged five to 11 years old who are in a clinical risk group, or who are household contacts of the immunosuppressed. On 16 February 2022, the Government subsequently accepted the JCVI’s advice to offer vaccination of children aged five to 11 years old not in a clinical risk group. However, the size and characteristics of a potential future wave were uncertain at the time of the JCVI’s advice, therefore it was not possible to determine the cost per quality adjusted life years gained.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 6 September 2021 to Question 38143 on Coronavirus: Research, what his timetable is for publication of the research funded by the National Institute for Health Research.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
Four of the eight projects have published at least one paper on their findings. We anticipate papers from the remaining four studies although we do not have a confirmed timetable for their publication.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the relative benefits of administering covid-19 vaccinations via aspiration compared to intravenous injection.
Answered by Maggie Throup
The UK Health Security Agency (UKHSA) has not made this assessment. The UKHSA provides guidance on immunisation techniques in Chapter Four of the Green Book, which follows available evidence and international recommendations for the administration of vaccines. This is reviewed and updated regularly by the UKHSA and states that it is not necessary to aspirate the syringe after the needle is introduced into the muscle because there are no large blood vessels at the recommended injection sites.
In addition, the only licensed route of administration for COVID-19 vaccines is via intra-muscular injection into the preferred site, the deltoid muscle. No assessment has therefore been made for intravenous injection. Vaccinations are not administered into the vein as this would be potentially harmful.